Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03260322
Title A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ITA | GBR | ESP | CAN


No variant requirements are available.